Nancy S. Miller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nancy S. Miller has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
Beverley Orr
Clinical Microbiology Laboratory, Boston Medical Center, Boston, MA, USA
3 shared publications- Edward C. Jones-Lopez
Section of Infectious Diseases, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA, USA
3 shared publications Belinda Yen-Lieberman
Cleveland Clinic, Cleveland, OH 44195
2 shared publicationsBeverley L. Orr
Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts 02118
2 shared publicationsDana Whitney
Department of Pharmacy, Boston Medical Center, Boston, Massachusetts
2 shared publicationsGuillermo Madico
Section of Infectious Diseases, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA, USA
2 shared publications
Latest Publications
- Open Access
- 14 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Unexpected detection of Mycobacterium tuberculosis DNA in US-born patients in putative association with clinical syndromes
Sequential inflammatory stages characterizing early tuberculosis (TB) disease and reports of differentially culturable M. tuberculosis have compounded existing gaps in the detection of paucibacillary TB disease, threatening global elimination goals. Here we report unanticipated results we encountered while conducting early development work for an ultrasensitive molecular TB assay that has been validated in various cohorts of patients with suspected TB disease. Detection of M. tuberculosis DNA (TB-DNA) was confirmed by an alternate molecular target and sequencing. Over a six-year period, we conducted three separate clinical studies (N = 297) that tested two sets of anonymized respiratory samples from patients hospitalized in two Boston hospitals, and a longitudinal observational study to determine clinical associations and outcomes. We found an unexpectedly high prevalence of TB-DNA in US-born patients and a potential association with acute chest syndrome in patients with sickle cell disease. These results are preliminary and will require further study in prospective studies that include clinical, radiological, immunological, and microbiological correlation.
- 14 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessUnexpected detection of Mycobacterium tuberculosis DNA in US-born patients in putative association with clinical syndromes
Sequential inflammatory stages characterizing early tuberculosis (TB) disease and reports of differentially culturable M. tuberculosis have compounded existing gaps in the detection of paucibacillary TB disease, threatening global elimination goals. Here we report unanticipated results we encountered while conducting early development work for an ultrasensitive molecular TB assay that has been validated in various cohorts of patients with suspected TB disease. Detection of M. tuberculosis DNA (TB-DNA) was confirmed by an alternate molecular target and sequencing. Over a six-year period, we conducted three separate clinical studies (N = 297) that tested two sets of anonymized respiratory samples from patients hospitalized in two Boston hospitals, and a longitudinal observational study to determine clinical associations and outcomes. We found an unexpectedly high prevalence of TB-DNA in US-born patients and a potential association with acute chest syndrome in patients with sickle cell disease. These results are preliminary and will require further study in prospective studies that include clinical, radiological, immunological, and microbiological correlation.
- Open Access
- 1 May 2023
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 2 (5)
Delayed Malaria Recrudescence and Relapse in the Setting of COVID-19
- 1 May 2023
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 2 (5)
Open AccessDelayed Malaria Recrudescence and Relapse in the Setting of COVID-19
- 4 March 2023
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 160 (1) , 11-17
Implementation of an HIV RNA Qualitative PCR Assay in an HIV Diagnostic Algorithm: A Single-Institution Experience
Objectives: Boston Medical Center (BMC) is a private, not-for-profit 514-bed academic medical center and legacy safety net hospital serving a diverse global patient population. BMC recently implemented a new HIV-1/HIV-2 Qualitative RNA PCR (HIV RNA QUAL) cleared by the US Food and Drug Administration to (1) replace antibody discrimination follow-up testing after a reactive fourth-generation (4G) serology screen and (2) use as a stand-alone diagnostic for suspected seronegative acute HIV infection. Methods: This report summarizes the results of a production monitor for the first 3 months postimplementation. Results: The monitor characterized test utilization, diagnostic turnaround time, impact on send-out testing, results reflexed to HIV RNA discrimination follow-up, and discrepancies between screening and HIV RNA results that necessitated additional investigation. Another element was the novelty of using HIV RNA QUAL while awaiting the existing Centers for Disease Control and Prevention HIV testing algorithm update. The 4G screening components and the HIV RNA QUAL were also used to create an algorithm specific to and compliant with current guidelines for screening patients on HIV preexposure prophylaxis. Conclusions: Based on our findings, this new test algorithm may be reproducible and instructive at other institutions.
- 4 March 2023
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 160 (1) , 11-17
Implementation of an HIV RNA Qualitative PCR Assay in an HIV Diagnostic Algorithm: A Single-Institution Experience
Objectives: Boston Medical Center (BMC) is a private, not-for-profit 514-bed academic medical center and legacy safety net hospital serving a diverse global patient population. BMC recently implemented a new HIV-1/HIV-2 Qualitative RNA PCR (HIV RNA QUAL) cleared by the US Food and Drug Administration to (1) replace antibody discrimination follow-up testing after a reactive fourth-generation (4G) serology screen and (2) use as a stand-alone diagnostic for suspected seronegative acute HIV infection. Methods: This report summarizes the results of a production monitor for the first 3 months postimplementation. Results: The monitor characterized test utilization, diagnostic turnaround time, impact on send-out testing, results reflexed to HIV RNA discrimination follow-up, and discrepancies between screening and HIV RNA results that necessitated additional investigation. Another element was the novelty of using HIV RNA QUAL while awaiting the existing Centers for Disease Control and Prevention HIV testing algorithm update. The 4G screening components and the HIV RNA QUAL were also used to create an algorithm specific to and compliant with current guidelines for screening patients on HIV preexposure prophylaxis. Conclusions: Based on our findings, this new test algorithm may be reproducible and instructive at other institutions.
- 1 December 2021
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 174 (12) , 1727-1732
Pandemic Response Requires Research Samples: A U.S. Safety-Net Hospital's Experience and Call for National Action
In response to the urgent need for understanding of the COVID-19 pandemic, authors describe their experience creating a biorepository at a safety-net hospital with a high proportion of underserved ... Biorepositories provide a critical resource for gaining knowledge of emerging infectious diseases and offer a mechanism to rapidly respond to outbreaks; the emergence of the novel coronavirus, SARS...
- 1 December 2021
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 174 (12) , 1727-1732
Pandemic Response Requires Research Samples: A U.S. Safety-Net Hospital's Experience and Call for National Action
In response to the urgent need for understanding of the COVID-19 pandemic, authors describe their experience creating a biorepository at a safety-net hospital with a high proportion of underserved ... Biorepositories provide a critical resource for gaining knowledge of emerging infectious diseases and offer a mechanism to rapidly respond to outbreaks; the emergence of the novel coronavirus, SARS...
- Open Access
- 21 August 2021
- Published by Wiley in Global Challenges
- Vol. 5 (11) , 2100039
On‐Site, On‐Demand 3D‐Printed Nasopharyngeal Swabs to Improve the Access of Coronavirus Disease‐19 Testing
Diagnostic testing that facilitates containment, surveillance, and treatment of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), or future respiratory viruses, depends on a sample collection device that efficiently collects nasopharyngeal tissue and that can be manufactured on site when an outbreak or public health emergency is declared by a government. Here two novel stereolithography‐based three‐dimensional (3D)‐printed nasopharyngeal swabs are reported which are made using a biocompatible and sterilizable photoresist. Such swabs are readily manufactured on‐site and on‐demand to ensure availability, if supply chain shortages emerge. Additionally, the 3D‐printed swabs easily adapt to current workflow and testing procedures in hospital clinical laboratories to allow for effortless scaling up of test kits. Finally, the 3D‐printed nasopharyngeal swabs demonstrate concordant SARS‐CoV‐2 testing results between the 3D‐printed swabs and the COPAN commercial swabs, and enable detection of SARS‐CoV‐2 in clinical samples obtained from autopsies.
- 21 August 2021
- Published by Wiley in Global Challenges
- Vol. 5 (11) , 2100039
Open AccessOn‐Site, On‐Demand 3D‐Printed Nasopharyngeal Swabs to Improve the Access of Coronavirus Disease‐19 Testing
Diagnostic testing that facilitates containment, surveillance, and treatment of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), or future respiratory viruses, depends on a sample collection device that efficiently collects nasopharyngeal tissue and that can be manufactured on site when an outbreak or public health emergency is declared by a government. Here two novel stereolithography‐based three‐dimensional (3D)‐printed nasopharyngeal swabs are reported which are made using a biocompatible and sterilizable photoresist. Such swabs are readily manufactured on‐site and on‐demand to ensure availability, if supply chain shortages emerge. Additionally, the 3D‐printed swabs easily adapt to current workflow and testing procedures in hospital clinical laboratories to allow for effortless scaling up of test kits. Finally, the 3D‐printed nasopharyngeal swabs demonstrate concordant SARS‐CoV‐2 testing results between the 3D‐printed swabs and the COPAN commercial swabs, and enable detection of SARS‐CoV‐2 in clinical samples obtained from autopsies.
- Top Cited Papers
- 4 January 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (1)
Recent endemic coronavirus infection is associated with less-severe COVID-19
Four different endemic coronaviruses (eCoVs) are etiologic agents for the seasonal common cold, and these eCoVs share extensive sequence homology with human SARS coronavirus 2 (SARS-CoV-2). Here, we show that individuals with, as compared with those without, a recent documented infection with eCoV were tested at greater frequency for respiratory infections but had a similar rate of SARS-CoV-2 acquisition. Importantly, the patients with a previously detected eCoV had less-severe coronavirus disease 2019 (COVID-19) illness. Our observations suggest that preexisting immune responses against endemic human coronaviruses can mitigate disease manifestations from SARS-CoV-2 infection.
- 4 January 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (1)
Top Cited PapersRecent endemic coronavirus infection is associated with less-severe COVID-19
Four different endemic coronaviruses (eCoVs) are etiologic agents for the seasonal common cold, and these eCoVs share extensive sequence homology with human SARS coronavirus 2 (SARS-CoV-2). Here, we show that individuals with, as compared with those without, a recent documented infection with eCoV were tested at greater frequency for respiratory infections but had a similar rate of SARS-CoV-2 acquisition. Importantly, the patients with a previously detected eCoV had less-severe coronavirus disease 2019 (COVID-19) illness. Our observations suggest that preexisting immune responses against endemic human coronaviruses can mitigate disease manifestations from SARS-CoV-2 infection.
- 1 September 2016
- Published by Elsevier in Clinica Chimica Acta
- Vol. 460, 203-210
Diagnosing sepsis – The role of laboratory medicine
- 1 September 2016
- Published by Elsevier in Clinica Chimica Acta
- Vol. 460, 203-210
Diagnosing sepsis – The role of laboratory medicine
- Open Access
- 8 July 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (7) , e0158371
Detection and Quantification of Mycobacterium tuberculosis in the Sputum of Culture-Negative HIV-infected Pulmonary Tuberculosis Suspects: A Proof-of-Concept Study
Rapid diagnosis of pulmonary tuberculosis (TB) is critical for timely initiation of treatment and interruption of transmission. Yet, despite recent advances, many patients remain undiagnosed. Culture, usually considered the most sensitive diagnostic method, is sub-optimal for paucibacillary disease. We evaluated the Totally Optimized PCR (TOP) TB assay, a new molecular test that we hypothesize is more sensitive than culture. After pre-clinical studies, we estimated TOP’s per-patient sensitivity and specificity in a convenience sample of 261 HIV-infected pulmonary TB suspects enrolled into a TB diagnostic study in Mbarara, Uganda against MGIT culture, Xpert MTB/RIF and a composite reference standard. We validated results with a confirmatory PCR used for sequencing M. tuberculosis. Using culture as reference, TOP had 100% sensitivity but 35% specificity. Against a composite reference standard, the sensitivity of culture (27%) and Xpert MTB/RIF (27%) was lower than TOP (99%), with similar specificity (100%, 98% and 87%, respectively). In unadjusted analyses, culture-negative/TOP-positive patients were more likely to be older (PM. tuberculosis genotypes identified in sputum by DNA sequencing exhibit differential growth in culture. These findings suggest that the TOP TB assay is accurately detecting M. tuberculosis DNA in the sputum of culture-negative tuberculosis suspects. Our results require prospective validation with clinical outcomes. If the operating characteristics of the TOP assay are confirmed in future studies, it will be justified as a “TB rule out” test.
- 8 July 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (7) , e0158371
Open AccessDetection and Quantification of Mycobacterium tuberculosis in the Sputum of Culture-Negative HIV-infected Pulmonary Tuberculosis Suspects: A Proof-of-Concept Study
Rapid diagnosis of pulmonary tuberculosis (TB) is critical for timely initiation of treatment and interruption of transmission. Yet, despite recent advances, many patients remain undiagnosed. Culture, usually considered the most sensitive diagnostic method, is sub-optimal for paucibacillary disease. We evaluated the Totally Optimized PCR (TOP) TB assay, a new molecular test that we hypothesize is more sensitive than culture. After pre-clinical studies, we estimated TOP’s per-patient sensitivity and specificity in a convenience sample of 261 HIV-infected pulmonary TB suspects enrolled into a TB diagnostic study in Mbarara, Uganda against MGIT culture, Xpert MTB/RIF and a composite reference standard. We validated results with a confirmatory PCR used for sequencing M. tuberculosis. Using culture as reference, TOP had 100% sensitivity but 35% specificity. Against a composite reference standard, the sensitivity of culture (27%) and Xpert MTB/RIF (27%) was lower than TOP (99%), with similar specificity (100%, 98% and 87%, respectively). In unadjusted analyses, culture-negative/TOP-positive patients were more likely to be older (PM. tuberculosis genotypes identified in sputum by DNA sequencing exhibit differential growth in culture. These findings suggest that the TOP TB assay is accurately detecting M. tuberculosis DNA in the sputum of culture-negative tuberculosis suspects. Our results require prospective validation with clinical outcomes. If the operating characteristics of the TOP assay are confirmed in future studies, it will be justified as a “TB rule out” test.
- Open Access
- 1 January 2016
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 62 (1) , 40
Commentary
- 1 January 2016
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 62 (1) , 40
Open AccessCommentary